Welcome to this week’s edition of The Friday Brief, in which the big attractions are INTERPHEX and acquisitions. At INTERPHEX in New York, our team engaged with companies along all points of the pharma value chain. Among these are some great upcoming, exclusive conversations with Dawsongroup tcs and Ecolab. Our editorial staff is busy churning out all of its content; you can look for it in the coming days at contractpharma.com.

Anytime there’s a major show in the industry, “breaking” news tends to slow down. But we do have a few noteworthy stories to share with you this week. Alcami has agreed to acquire Tjoapack, expanding Alcami’s presence in Europe. UCB has proposed a $650 million acquisition of Neurona Therapeutics. Servier completed the tender offer to buy out all stock of Day One Biopharmaceuticals. And Asahi Kasei completed its acquisition of Aicuris.

In collaborations, Merck is betting up to $1 billion on a partnership with Google Cloud to enhance Merck’s AI solutions. Andelyn Biosciences and ENCell are establishing a strategic manufacturing bridge between the U.S. and the Asia Pacific region.

And a few companies are expanding their capacities. AbbVie is making a $1.4 billion investment on a 185-acre pharma manufacturing campus in North Carolina. Meanwhile, Evonik will expand its biotech capabilities in Slovakia.

Still plenty going on this week, but again, stay up to date at contractpharma.com for our wrap-up coverage from INTERPHEX. And we’ll see you next week.